作者: Matthias Lorenz , Hans-Helge Müller ,
DOI: 10.1200/JCO.2000.18.2.243
关键词: Colorectal cancer 、 Tolerability 、 Gastroenterology 、 Multicenter trial 、 Floxuridine 、 Hepatic arterial infusion 、 Internal medicine 、 Fluorouracil 、 Rectum 、 Medicine 、 Chemotherapy
摘要: PURPOSE: To assess the efficacy and tolerability of three treatments for patients with documented adenocarcinoma colon and/or rectum who have undergone complete resection primary tumor nonresectable liver metastases that do not exceed 75% volume. PATIENTS AND METHODS: A total 168 at 25 treatment centers were enrolled onto this prospective, multicenter, randomized study. The arms as follows: (1) fluorouracil (5-FU)/leucovorin (LV) administered via hepatic arterial infusion (HAI), (2) 5-FU/LV intravenous (IV) infusion, (3) fluorodeoxyuridine (FUDR) HAI. RESULTS: Median times to disease progression 9.2 months treated HAI 5-FU/LV, 6.6 IV 5.9 FUDR. survival FUDR 18.7 months, 17.6 12.7 respectively. There was a ne...